NXT USA Brings Digestive Health and NAD+ Preservation Innovation to Vitafoods Asia 2026

NXT USA will exhibit at Vitafoods Asia 2026, running September 2–4 at the Queen Sirikit National Convention Center in Bangkok, Thailand. At Stand H6-F21, the company plans to present human clinical research on four proprietary ingredients spanning digestive health, healthy aging, women's hormonal health, and joint support — categories the company has identified as among the most active in the supplement industry.¹

The company's Asia-Pacific team and senior leadership will be on-site, including managing director Eric Anderson, chief growth officer Elise Kaiser, sales manager Divya Dubey, and VP Korea David Woo, alongside Hiroyuki Tanaka, CEO of Japan partner Octroll. According to Anderson, the event provides an opportunity to connect with regional brands and formulators around the company's ongoing clinical research program. “We continue to invest in human clinical research that gives formulators meaningful data, practical formulation options, and compelling points of differentiation in categories that matter to today’s consumers,” he stated.

NXT USA and Laila Nutra will be available throughout Vitafoods Asia to discuss clinical data, formulation options, and new product development with attendees.

Which Four Ingredients Will NXT USA Feature at Vitafoods Asia?

Digexin, a botanical ingredient studied for digestive regularity and comfort, is being presented with new research examining microbial function and short-chain fatty acid production. The company reports that some effects have been observed within seven days of use. A recent ex vivo study conducted by ProDigest using human colon simulation models found that the ingredient, a proprietary extraction of okra and ashwagandha, increased production of short-chain fatty acids, particularly butyrate, without relying on fermentable fiber or live bacteria.²

BluNAD Booster, a plant-based ingredient for the NAD+ and healthy-aging categories, is described as supporting NAD+ levels through two mechanisms: promoting the body's own NAD+ production pathways and reducing activity of the CD38 enzyme, which breaks NAD+ down. Conference research on the ingredient reported lower CD38 activity alongside higher NAD+ levels and improvements in cognitive performance, quality of life, and physical endurance.³

Xeya Modern Shatavari is positioned as a standardized version of a traditional Ayurvedic botanical for women's hormonal health, with human clinical research cited across multiple life stages. The company notes an effective dose range of 50–100 mg per day, which it says allows flexibility in combination formulas.

TamaFlex, a Curcuma longa and Tamarindus indica extract blend for joint health, is described as producing measurable benefits within five days. This is consistent with published research on the ingredient category more broadly: a randomized trial of more than 1,100 adults with osteoarthritis found that a 250-mg dose of the blend improved WOMAC pain and function scores relative to placebo, with benefits reported as early as day five, alongside reductions in the inflammatory marker hs-CRP and the cartilage-breakdown marker urinary CTX-II.⁴ Recent coverage from Nutritional Outlook of the joint health category noted a broader trend toward ingredients that combine rapid, multidimensional clinical validation — spanning patient-reported outcomes, biomarkers, and functional testing — with low effective doses that leave room for combination formulations.

NXT USA states that its ingredients support women’s health, gut health, energy, brain function, and joint wellness. Anderson highlighted the rationale behind the company’s focus on the research behind its ingredients. “Our focus has always been on developing ingredients that combine strong science with real-world formulation advantages,” he explained. “Clinical validation helps our customers move beyond trends and build products around benefits that are meaningful, measurable, and supported by research.”

References

1. NXT USA. NXT USA to showcase clinically validated ingredient innovations at Vitafoods Asia 2026. August 24, 2026. Accessed August 25, 2026.
2. Saraceno N. Digexin Study Shows Butyrate-Forward Microbiome Modulation Without Fiber or Live Biotics. Nutritional Outlook. May 4, 2026. Accessed August 25, 2026. https://www.nutritionaloutlook.com/view/digexin-study-shows-butyrate-forward-microbiome-modulation-without-fiber
3. Saraceno N. Research spotlights CD38 inhibition as a strategy for NAD+ preservation. Nutritional Outlook. June 15, 2026. Accessed August 25, 2026. https://www.nutritionaloutlook.com/view/research-spotlights-cd38-inhibition-nad-preservation
4. Saraceno N. Emerging joint health ingredients target faster relief and long-term support. Nutritional Outlook. March 20, 2026. Accessed August 24, 2026. https://www.nutritionaloutlook.com/view/emerging-joint-health-ingredients-faster-relief-long-term-support